论文部分内容阅读
目的：比较氟替卡松与培氯米松治疗成人哮喘的疗效。方法：采用随机双盲对照方法，氟替卡松组２１例（男性１１例，女性１０例，年龄４６±ｓ１２ａ），用氟替卡松干粉剂２００μｇ，吸入，ｂｉｄ，６ｗｋ为一个疗程。培氯米松组１９例（男性１２例，女性７例，年龄４３±１１ａ），用培氯米松干粉剂４００μｇ，吸入，ｂｉｄ，６ｗｋ为一个疗程。结果：氟替卡松组和培氯米松组的早晨最大呼气流量（ＰＥＦ）均增加，症状评分及沙丁胺醇气雾剂用量均减少，肺功能明显改善，但２组间比较无明显差异（Ｐ＞０．０５）。治疗前后２组血浆氢化可的松均在正常范围内，２组间比较Ｐ＜０．０５。结论：２组治疗哮喘皆有效。
Objective: To compare the efficacy of fluticasone and beclomethasone in the treatment of adult asthma. Methods: 21 patients (11 males and 10 females, age 46 ± s12a) were treated with fluticasone in a randomized, double-blind, placebo-controlled trial of fluticasone dry powder 200 μg inhaled bid twice daily for 6 weeks. 19 patients (12 males and 7 females, age 43 ± 11a) were treated with beclomethasone in a dose of 400 μg. Results: The morning peak expiratory flow (PEF) in both fluticasone and beclomethasone groups were increased, the symptom scores and salbutamol aerosol dosage were decreased, lung function was significantly improved, but there was no significant difference between the two groups (P> 0. 05). Before and after treatment, the two groups of plasma hydrocortisone were in the normal range, P <0.05 between the two groups. Conclusion: Both groups are effective in treating asthma.